作者: Xu, Jie ; He, Huacheng ; Ezekiel, Odinaka Cassandra ; Wu, Jiang ; Li, Yue ; Zhang, Jian ; Luo, Yuting ; Li, Bingxin ; Xiao, Jian ; Huang, Wen ; Zhang, Shihui ; Shi, Huiling ; Li, Xiaokun ; Li, Jie

AbstractSevere burn wounds usually destroy key cells’ functions of the skin resulting in delayed re‐epithelization and wound regeneration. Promoting key cells’ activities is crucial for burn wound repair. It is well known that keratinocyte growth factor‐2 (KGF‐2) participates in the proliferation and morphogenesis of epithelial cells while acidic fibroblast growth factor (aFGF) is a key mediator for fibroblast and endothelial cell growth and differentiation. However, thick eschar and the harsh environment of a burn wound often decrease the delivery efficiency of fibroblast growth factor (FGF) to the wound site. Therefore, herein a novel microneedle patch for sequential transdermal delivery of KGF‐2 and aFGF is fabricated to enhance burn wound therapy. aFGF is first loaded in the nanoparticle (NPaFGF) and then encapsulated NPaFGF with KGF‐2 in the microneedle patch (KGF‐2/NPaFGF@MN). The result shows that KGF‐2/NPaFGF@MN can successfully get across the eschar and sequentially release KGF‐2 and aFGF. Additional data demonstrated that KGF‐2/NPaFGF@MN achieved a quicker wound closure rate with reduced necrotic tissues, faster re‐epithelialization, enhanced collagen deposition, and increased neo‐vascularization. Further evidence suggests that improved wound healing is regulated by significantly elevated expressions of hypoxia‐inducible factor‐1 alpha (HIF‐1ɑ) and heat shock protein 90 (Hsp90) in burn wounds. All these data proved that KGF‐2/NPaFGF@MN is an effective treatment for wound healing of burns.

2024-05-01·Neurotrauma Reports

Recombinant Acidic Fibroblast Growth Factor Facilitates Motor Recovery and Reduces Myelomalacia in Traumatic American Spinal Injury Association Impairment Scale A Spinal Cord Injured Patients

Article

作者: Huang, Chiau-Li ; Chang, Wan-Ya ; Huang, Shih-Fong ; Tsai, Yun-An ; Huang, Wen-Cheng ; Fay, Li-Yu ; Hsu, Shu-Shong ; Su, Yi-Tien ; Yang, Lin-Hsue ; Lee, Ya-Hui

This study aims to evaluate the potential benefits of treating spinal cord injury (SCI) patients with acidic fibroblast growth factor (aFGF), a potent neurotrophic factor that preserves neuronal survival. The study involved 12 tetraplegic patients with American Spinal Injury Association Impairment Scale (AIS) Grade A SCI who were randomly assigned to receive either a recombinant human aFGF or a placebo every 4 weeks for three doses. Participants underwent comprehensive evaluations of medical, neurological, and functional parameters at baseline and every 4 weeks after the first dose until the 48th week. The first dose was administered directly to the injury site during surgery within 6 weeks of the SCI, while the subsequent two doses were administered via lumbar puncture with a 4-week interval. The results revealed promising beneficial effects of aFGF on AIS Grade A SCI patients. The study report highlights aFGF's potential to expedite motor recovery in complete SCI patients and significantly increase the probability of a 10-point improvement when compared to the placebo group (odds ratio = 6.06, p = 0.0004). Furthermore, aFGF treatment exhibited a significant reduction (p < 0.01) in the incidence or exacerbation rate of myelomalacia, a known secondary complication following SCIs.

2024-01-01·Burns & Trauma

Acidic fibroblast growth factor inhibits reactive oxygen species-induced epithelial–mesenchymal transdifferentiation in vascular endothelial cells via the miR-155-5p/SIRT1/Nrf2/HO-1 pathway to promote wound healing in diabetic mice

Article

作者: Xiao, Yujie ; Hei, Fenghui ; Liu, Yang ; Zhang, Yue ; Han, Juntao ; Hu, Dahai ; Wang, Hongtao

AbstractBackgroundDiabetic chronic wounds are among the most common and serious complications of diabetes and are associated with significant morbidity and mortality. Endothelial-to-mesenchymal transition (EndMT) is a specific pathological state in which endothelial cells are transformed into mesenchymal cells in response to various stimuli, such as high glucose levels and high oxidative stress. Acidic fibroblast growth factor (aFGF), which is a member of the fibroblast growth factor family, possesses strong antioxidant properties and can promote the differentiation of mesenchymal stem cells into angiogenic cells. Therefore, we investigated the role of aFGF in EndMT in diabetic wounds and analysed the underlying mechanisms.MethodsA diabetic mouse model was used to verify the effect of aFGF on wound healing, and the effect of aFGF on vascular endothelial cells in a high-glucose environment was examined in vitro. We examined the expression of miR-155-5p in a high-glucose environment and the miR-155 downstream target gene SIRT1 by luciferase reporter assays.ResultsaFGF promoted wound closure and neovascularization in a mouse model of type 2 diabetes. In vitro, aFGF inhibited the production of total and mitochondrial reactive oxygen species (ROS) in vascular endothelial cells and alleviated epithelial–mesenchymal transdifferentiation in a high-glucose environment. Mechanistically, aFGF promoted the expression of SIRT1 and the downstream targets Nrf2 and HO-1 by negatively regulating miR-155-5p, thereby reducing ROS generation.ConclusionsIn conclusion, our results suggest that aFGF inhibits ROS-induced epithelial–mesenchymal transdifferentiation in diabetic vascular endothelial cells via the miR-155-5p/SIRT1/Nrf2/HO-1 axis, thereby promoting wound healing.

项与重组人酸性成纤维细胞生长因子相关的新闻（医药）

2021-03-03

·药融圈

坐标上海：腾瑞制药拟IPO

▲速抢免费参会名额 | 大湾区(广州)生物医药创新者峰会 1.腾瑞制药从事生物药、化学药、原料药等产品的研发、生产、销售，产品涵盖烧伤科、外科、消化科、抗感染科和心脑血管科等领域。公司核心产品“艾夫吉夫” ——“外用重组人酸性成纤维细胞生长因子”，主要用于烧面创伤及慢性溃疡创面的愈合，为国家一类新药，属于国家医保乙类药品。“艾夫吉夫”采用基因重组技术研制，系唯一获批的外用重组人酸性成纤维细胞生长因子类的生物制剂药物。公司主要在研产品“重组巴曲酶”是目前唯一采用基因工程合成的血凝酶药物，在临床上主要用于外科、妇产科手术前后出血的预防和治疗，以及消化道出血、新生儿出血等，目前处于Ⅲ期临床试验阶段。公司生产与销售的化学药品主要为阿昔洛韦片、琥乙红霉素片、复方氢氧化铝片、西咪替丁片、鱼腥草素钠片等普药，广泛应用于外科、消化科、呼吸内科等领域。 2020 年上半年新冠疫情爆发后，公司积极组织开展口罩等防疫物资生产，新增口罩生产销售业务。公司已取得上海市药品监督管理局颁发的《医疗器械生产企业许可证》及相关产品的医疗器械产品注册证。 2.药融圈获悉，公司目前情况：辅导备案就位，正在上市辅导中。 3.股东构成：叶桃先生直接和间接合计可以控制公司 36.84%的股份，为公司的实际控制人。叶桃先生， 1976 年 2 月出生，中国国籍，无境外永久居留权，毕业于上海中医药大学药学院（学士）、并取得长江商学院高级管理人员工商管理硕士学位（EMBA）。现攻读上海交通大学上海高级金融学院博士。2001 年 7 月至 2003年 7 月，就职于上海雷允上药业有限公司担任车间工艺员、团委书记；2004 年 1月至 2004 年 12 月就职于上海辉瑞制药有限公司担任医药销售代表；2005 年 1月至 2010 年 9 月就职于上海腾瑞生物医药科技有限公司担任董事长、 CEO；2010年 9 月至今任公司董事长、 CEO。更多信息，请扫免费的药融云数据或网站 www.pharnexcloud.com 【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。点分享点点赞点在看